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Abstract
Oxidative stress contributes to the development of pulmonary hypertension in experimental
models, but this association in humans is unknown. We investigated the relationship between
pulmonary artery systolic pressure measured by echocardiography and plasma aminothiol
oxidative stress markers, with the hypothesis that oxidative stress will be higher in those with
pulmonary hypertension. A group of 347 patients aged 65±12 years from the Emory
Cardiovascular Biobank underwent echocardiographic assessment of left ventricular ejection
fraction and pulmonary artery systolic pressure. Plasma aminothiols, cysteine, its oxidized form,
cystine; glutathione, and its oxidized disulphide (GSSG) were measured and the redox potentials
(Eh) of cysteine/cystine and glutathione/GSSG couples were calculated. Non-normally distributed
variables were log transformed (Ln). Univariate predictors of pulmonary artery systolic pressure
included age (p<0.001), gender (p=0.002), mitral regurgitation (p<0.001), left ventricular ejection
fraction (p<0.001), left atrial size (p< 0.001), diabetes (p=0.03), Plasma Ln cystine (β=9.53,
p<0.001), Ln glutathione (β =-5.4, p=0.002), and Eh glutathione (β =0.21, p=0.001). A multivariate
linear regression model adjusting for all confounding variables demonstrated that Ln cystine
(β=6.56, p=0.007), mitral regurgitation (β= 4.52, P<0.001), statin use (β =-3.39, p=0.03), left
ventricular ejection fraction (β=-0.26, p=0.003), and age (β=0.17, p=0.003) were independent
predictors of pulmonary artery systolic pressure. For each 1% increase in plasma cystine,
pulmonary artery systolic pressure increased by 16%. This association persisted in the subgroup
with preserved left ventricular ejection fraction (≥50%) and no significant mitral regurgitation.
Whether treatment of oxidative stress will improve pulmonary hypertension requires further study.
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Introduction
Pulmonary hypertension (PH) is defined as persistent elevation of mean pulmonary artery
pressure above 25 mmHg.1 Although Group 1 PH is a rare and progressive life-threatening
disease, mild to moderate PH secondary to a variety of cardiac and pulmonary disorders is
far more common.2, 3 Underlying pathophysiologic changes include pulmonary arterial
smooth muscle proliferation, endothelial dysfunction, oxidative stress (OS), and
inflammation.4 OS is also associated with aging and several chronic ailments including
cardiovascular disease (CVD),5 diabetes,6 and chronic pulmonary disease.7 In experimental
models, OS characterized by increased levels of reactive oxygen species, contributes to the
development of PH and subsequent right ventricular remodeling.8-11 Similarly, increased
intracellular calcium flux, mediated by higher OS, leads to smooth muscle contraction and
higher pulmonary artery systolic pressure (PASP),12 and improvement of OS decreases
PASP and improves right ventricular dysfunction.4, 13-15 However, few human studies have
explored the link between OS and PH.16, 17
Aminothiol compounds play a crucial role in redox signaling and can be quantified in
plasma to assess OS burden in vivo.18 Of these, cysteine constitutes the major extracellular
thiol pool which reacts readily with oxidants to form its disulphide cystine which is an
abundant and sensitive indicator of systemic oxidant burden.19 Intra-cellularly, glutathione
is a major antioxidant that helps eliminate peroxides and maintains redox state.20 The Nernst
equation may be used to calculate the redox potentials of both the glutathione and cysteine
pools. Increased OS, measured as lower levels of glutathione and/or higher levels of cystine,
or a more oxidized redox potential, is associated with CVD risk factors, CVD, subclinical
vascular disease, and importantly with adverse outcomes.21-28
To investigate the association of plasma aminothiols with PASP, we measured plasma levels
of aminothiols and estimated PASP using surface echocardiography, with the hypothesis
that increased OS, characterized as a higher cystine level will be associated with increased
PASP in humans.
Methods
Study participants were recruited as part of the Emory Cardiovascular Biobank, consisting
of 347 patients aged between 53 and 77 years enrolled prior to undergoing cardiac
catheterization for confirmed or suspected CAD across three Emory Healthcare sites
between 2004 and 2008. Subjects with connective tissue disease, HIV infection, liver
disease, congenital heart disease, sickle cell disease, or other systemic inflammatory
conditions were excluded. Patients' demographic characteristics, medical history, and
behavioral (lifestyle) habits were collected by interview. Risk factor prevalence was
determined by physician diagnosis and/or treatment for hypertension, hyperlipidemia, and
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diabetes. Smoking was classified as non-smoker or “ever smoked” if there was a lifetime
history of smoking at least 100 cigarettes. Medical records were reviewed to confirm self-
reported history of cardiovascular or pulmonary diseases. The study was approved by the
Emory University Institutional Review Committee and all subjects provided informed
consent.
Each subject underwent transthoracic echocardiographic assessment of left ventricular
ejection fraction (LVEF), mitral regurgitation (MR), left atrial (LA) size, and estimation of
PASP. Echocardiographic measurements were all performed according to the American
Society of Echocardiography recommendations.29 PASP was estimated using the velocity of
the tricuspid regurgitant jet based on the simplified Bernouli equation (PASP=4VTR2 + right
atrial pressure) where VTR is the peak velocity of the tricuspid regurgitant jet measured by
continuous-wave Doppler.30 Estimation of the severity of MR was performed by assessment
of vena contracta using color Doppler echocardiography with values <0.3 mm
corresponding to mild MR; 0.3 to 0.69 mm as moderate MR, and >0.7 mm as severe MR by
personnel who were blinded to the OS data. Severity of coronary artery disease was assessed
by the Gensini score with two operators who independently evaluated all coronary
angiograms. This score uses a point system for the degree of luminal narrowing along with a
multiplier for specific coronary tree locations, thereby weighting each lesion score for
prognostic significance. The total of the lesion scores is summed to give a final Gensini
score.31
Measurement of plasma aminothiol levels
Plasma levels of cysteine, its oxidized form, cystine, glutathione, and its oxidized disulphide
(GSSG) were measured and the ratios of cysteine/cystine and glutathione/GSSG were
calculated and expressed as redox potentials, Eh cystine and Eh glutathione, respectively,
where a more oxidized value has a more positive numeric value. Detailed methods for the
measurements of aminothiols in plasma have been described previously. 24, 26, 32, 33 Briefly,
samples were collected directly into specially prepared tubes containing a preservative to
retard auto-oxidation, centrifuged, and the supernatant frozen at -80°C, which shows no
significant loss for 1 year. Analyses by high performance liquid chromatography were
performed after dansyl derivatization on a 3-aminopropyl column with fluorescence
detection. Metabolites were identified by co-elution with standards and quantified by
integration relative to the internal standards, with validation relative to external standards.
Issues of sample collection, stability, analysis, and standardization have been extensively
studied, and the method has been used in several clinical studies.34
Statistical Analysis
Mean±standard deviation (SD) and proportions are used to describe continuous and
dichotomous variables, respectively. Spearman correlation test was used to determine
bivariate correlations between aminothiols and PASP. Kolmogorov-Smirinov test was used
to determine normality. Where data was not normally distributed, natural logarithm (Log)
transformation was performed. Multivariate linear regression including all variables with
P≤0.20 in univariate analyses were used to determine independent predictors of PASP.
Regression coefficients are presented as point estimates with 95% confidence intervals.
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Binary logistic regression was performed to investigate independent predictors of pulmonary
hypertension as defined by PASP≥50 mmHg. Only p values ≤ 0.05 were considered
significant. Analyses were performed using the SPSS 20.0 software (SPSS Inc., USA).
Results
A total of 347 subjects undergoing coronary angiography, 61% male, mean age 65±12 years,
with and without coronary artery disease were enrolled (Table 1). Subjects had multiple risk
factors, 15% presented with acute myocardial infarction, and 5% had a history of chronic
lung disease.
Relationship of plasma amoinothiols with cardiovascular risk factors
Plasma cystine, glutathione, and Eh glutathione significantly correlated with age (r=0.32,
p<0.0001; r=-0.12, p=0.02; and r=0.13, p=0.01, respectively). Diabetics had significantly
higher levels of cystine (117±40 μM vs. 102±29 μM, p=0.00008) and lower glutathione
(1.18±0.6 μM vs. 1.3±0.6 μM, p=0.04) compared to non-diabetics. History of hypertension
was associated with higher cystine (112±36 μM vs. 94±22 μM, p=0.00001). We observed no
difference in plasma aminothiol levels between males and females.
Plasma cystine level correlated with glutathione (r=-0.13, p=0.01), cysteine (r=0.39,
p<0.001), and Eh glutathione (r=0.17, p=0.001) levels. Plasma aminothiols did not correlate
with serum C-reactive protein (CRP) levels (r=-0.01, p=0.77 for cystine).
Relationship between aminothiol markers of OS and PASP
Using linear regression, univariate predictors of PASP included Ln cystine (p<0.001), Ln
glutathione (p=0.002), and Eh glutathione (p=0.001) with Ln cysteine (p=0.06) trending
towards significance, Table 2, Figure 1. Additionally, PASP was higher in females
(p=0.005), in those with MR (P<0.001) with a trend towards higher PASP in diabetics
(p=0.06). Other univariate correlates of PASP were age (p<0.001), LA size (p<0.001) and
LVEF (p<0.001), Table 2.
A multivariate linear regression model that included age, gender, diabetes, statin use,
presence of MR, LVEF, LA size, Gensini score, CRP as well as Ln cystine, Ln glutathione,
and Eh glutathione, revealed Ln cystine (p=0.007), MR (p<0.001), statin use (p=0.03), LVEF
(p=0.003), and age (p=0.003) as independent predictors of PASP, Table 2. Ln cysteine was
not included in the multivariate model given its high collinearity with Ln cystine.
Relationship between PH and markers of OS
When divided into groups with normal PASP ≤25 mmHg, those with PASP ≥50 mmHg, and
the intermediate group of PASP 26-49 mmHg, there was a graded increase in PASP with
greater OS, Figure 2. In a multivariate analysis of correlates of PASP ≥ 50 mmHg that
included age, gender, diabetes, statin use, MR, LVEF, LA size, Gensini score, Ln
glutathione, Eh gluthatione, and CRP, Ln cystine was again a significant predictor (β=1.86,
p=0.028).
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Subgroup Analysis
Association of OS markers with PASP in patients with normal LVEF and
insignificant MR—In order to investigate the effects of OS on PASP without the
confounding effects of low LVEF and MR that may also be associated with OS, we
analyzed patients with normal LVEF (≥50%) and those free of moderate or severe MR. In
this subset of 217 subjects, a multivariate linear regression model controlling for age,
gender, diabetes, statin use, LA size, Gensini, CRP as well as Ln cystine, Ln glutathione, and
Eh glutathione, revealed only Ln cystine as an independent OS marker predicting PASP
(β=6.82, p=0.009). Moreover, Ln cystine was significantly higher in patients with PASP ≥
50 mmHg compared to those with PASP between 26-49 mmHg and those with PASP ≤ 25
mmHg (p=0.003).
Association of OS markers with PASP in patients without chronic lung
disease—In order to investigate whether the observed association of OS markers exists
even in those without a diagnosis of chronic lung disease, we excluded these subjects
(N=19, 5%). Linear regression model adjusting for the aforementioned variables revealed an
independent association between Ln cystine and PASP (β=5.6, p=0.03) in the remaining
subjects.
Discussion
Herein, we report that a higher level of plasma aminothiols, representing non-free radical OS
burden, is associated with higher PASP assessed by echocardiography, independent of other
clinical and echocardiographic risk factors including MR and left ventricular dysfunction.
Every 1% increase in plasma cystine level was associated with a 16% increase in PASP. To
our knowledge this is the first study in humans to explore the relationship between readily
measurable plasma markers of OS and PASP.
Inflammatory and oxidative changes are present in the lung vasculature in PH and patients
with systemic inflammatory conditions such as lupus or scleroderma are at risk for PH.35
Patients with established PH have up-regulation of inflammatory mediators such as
intracellular adhesion molecule-1 (ICAM-1) and endothelial leukocyte adhesion molecule-1
(ELAM-1),36 and anti-inflammatory therapy has been invariably associated with decreases
in PASP in experimental models.37
The putative role of OS in the pathophysiology of PH is supported by experimental data.
Renin over-expressing rats have higher intrapulmonary NADPH oxidase activity and higher
right ventricular systolic pressure.11 Conversely, reduction in NADPH oxidase activity in
the gp91phox knockout mice decreases hypoxia-induced generation of reactive oxygen
species and abolishes pathophysiological changes in the pulmonary artery.38 Furthermore,
xanthine oxidase-mediated increase in reactive oxygen species expression in neonatal rats
exposed to chronic hypoxia has been shown to result in PH.39 In lung tissues from patients
with pulmonary arterial hypertension, increased nitrotyrosine and 8-hydroxyguanosine
activities have been noted.16 Finally, in a murine model of PH, lower superoxide dismutase
(SOD2) activity was reported,40 findings similar to those observed in lung tissue harvested
from patients with PH at autopsy. Increased proliferation of pulmonary artery smooth
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muscle cells was ameliorated by SOD2 augmentation.40 These data along with our findings
of an independent association of OS markers with PASP, even in early stages of PH,
suggests a pathophysiologic role for OS in the development of human PH.
Plasma aminothiols are reliable measures of systemic oxidative burden, with glutathione
representing intracellular and the cysteine/cystine pools reflecting extracellular oxidative
burden.18 While we did not observe any significant independent association with glutathione
or its redox potential Eh glutathione, the oxidized disulfide cystine, was independently
associated with PASP.
We have previously shown that aminothiol markers of OS are associated with
cardiovascular risk factors including hypertension, endothelial dysfunction, increased
systemic arterial stiffness, increased carotid wall thickness, even in relatively healthy
subjects without risk factors, and with worse long term outcomes.23-26, 35-42 This study
extends our findings to hypertension in the pulmonary circulation. To ensure that risk factors
for atherosclerosis were not responsible for our observed association, we controlled for all
known and measured risk factors including medications, and found that the association of
PASP with OS persisted. Similarly, we adjusted for presence of significant MR, left
ventricular dysfunction, and significant coronary artery disease, all known to be associated
with PH. Thus, even in the subset with absence of significant MR and left ventricular
dysfunction, plasma cystine was a predictor of PASP independent of other risk factors
including systemic inflammation, measured as plasma CRP level. A PASP of 38 mmHg is
considered the best discriminatory cut-off value corresponding to mean pulmonary artery
pressure of 25 mmHg for diagnosis of PH.43 We chose a higher cutoff of 50 mmHg in this
study to further reduce the potential of false positive high PASP readings with
echocardiography. We found that plasma cystine is significantly higher in those with PASP
≥ 50 mmHg than those with PASP ≤ 25 and PASP between 26-49 mmHg.
Despite a large body of evidence on the association of OS with PH especially in animal
models, it remains uncertain whether antioxidant therapy would be a useful therapeutic
modality in patients with PH.44 This may have been partly secondary to the lack of well-
designed randomized controlled clinical trials with therapies targeted to OS pathways as
almost all studies to date have investigated the effect of non-targeted antioxidant compounds
in experimental models of PH with overall mixed results.45, 46
Future studies need to validate our results and investigate whether plasma cystine can
predict PH as well as be used to monitor the severity of the disease.
Strengths and limitations
This is the first study to demonstrate an independent association between readily available
plasma markers of systemic OS with PASP. A limitation of our study is the potential
inaccuracy in measuring PASP with echocardiography. However, it remains the most widely
used method for non-invasive screening of PH that is highly correlated with direct pressure
measurements during right heart catheterization with a pooled sensitivity and specificity of
83% and 72%, respectively.43, 47, 48 We may have underestimated the prevalence of chronic
lung disease as this diagnosis was obtained from the history and chart review. Noneheless,
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the independent association between PASP and cystine persisted even after excluding
subjects with chronic lung disease. We acknowledge that findings from this study might not
be generalizable to all subcategories of PH.49
Conclusion
Increased plasma OS burden, estimated as increased circulating levels of cystine is
associated with increased PASP.
Perspectives
In this study for the first time we have shown that novel plasma aminothiol markers of OS
are associated with PASP independent of traditional cardiovascular risk factors as well as
presence of chronic lung disease, significant MR, and depressed left ventricular systolic
function. Whether treatment of PH can be monitored using aminothiol markers and whether
targeted treatment of OS that normalizes aminothiol levels will improve PH requires further
investigation. Future studies are also needed to investigate the association of these
aminothiol markers with PASP in different subcategories of PH.
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Abbreviations and Acronyms
PH Pulmonary Hypertension
PASP Pulmonary Artery Systolic Pressure
LVEF Left Ventricular Ejection Fraction
MR Mitral Regurgitation
LA Left Atrium
CRP C-Reactive Protein
GSSG Oxidized Glutathione
Eh Cystine Redox potential for cystine
Eh Glutathione Redox potential for glutathione
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Novelty and Significance
What is New?
To our knowledge this is the first study in humans to investigate the association between
readily measurable plasma markers of systemic OS and PH. Every 1% increase in plasma
cystine level was associated with a 16% increase in PASP.
What is Relevant?
Whether these measurements can be used to titrate therapy and whether anti-oxidants that
normalize aminothiol levels will be therapeutic for PH needs to be investigated.
Summary
In summary, plasma cystine is associated with PASP independent of other risk factors
and even in those with normal left ventricular systolic function and no significant MR.
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Figure 1.
Relationship between aminothiol levels and PASP. Panels A, B, and C demonstrate bivariate
correlations of PASP with Ln cysteine, Ln glutathione, and Eh glutathione respectively.
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Figure 2.
Differences in aminothiol levels in subjects with normal PASP (≤25 mmHg), and mild or
moderate PH.
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Table 1
Baseline Characteristics
Predictors All (N=347)
Age (years) 65±12
Male Gender (%) 61
African American (%) 16
BMI (kg/m2) 26±11
Hypertension (%) 71
Diabetes (%) 34
Acute Myocardial Infarction 15
Smoking (%) 12
Pulmonary Disease (%) 5
Statin Use (%) 70
Beta-Blocker Use (%) 71
Mitral Regurgitation (%) 84
 -Mild 66
 -Moderate 23
 -Severe 11
LVEF (%) 50±15
LA Size (cm) 4.2±0.8
LV hypertrophy (%) 15
Gensini score 52±70
Cystine (μM) 107.2±33.7
Cysteine (μM) 13.4±5.8
Glutathione (μM) 1.27±0.62
GSSG (μM) 0.03±0.03
Eh Glutathione (mV) -136.1±11.7
Eh Cysteine (mV) -75.3±9.1
CRP (mg/L) 9±17.5
Data presented as Mean±SD. BMI: Body Mass Index, CRP: C - reactive protein, LVEF: Left Ventricular Ejection Fraction, MI: Myocardial
Infarction, LA: Left atrium.
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Table 2
Univariate and Multivariate Correlates of PASP
Characteristics Univariate Linear Regression Multivariate Linear Regression
Beta P value Beta P value
Age 0.27 <0.001 0.19 0.003
Male Gender -4.38 0.005 -1.94 0.16
African American 1.22 0.55 -- --
Hypertension 0.40 0.81 -- --
Diabetes 2.94 0.06 1.46 0.32
BMI (kg/m2) -0.007 0.92 -- --
Acute MI -0.68 0.74 -- --
Smoking -2.26 0.33 -- --
Pulmonary Disease 0.33 0.92 -- --
Statin Use -1.92 0.20 -3.12 0.03
Beta-Blocker Use 0.47 0.76 -- --
LA Size 4.71 <0.001 1.41 NS
Mitral Regurgitation 5.02 <0.001 4.52 <0.001
LVEF -0.26 <0.001 -0.12 0.003
Gensini score 0.015 0.18 0.004 NS
CRP (mg/L) 0.06 0.18 0.01 NS
Ln Cystine (μM) 9.53 <0.001 6.56 0.007
Ln Cysteine (μM) 3.76 0.06 -- --
Ln Glutathione (μM) -5.43 0.002 -0.30 NS
Ln GSSG (μM) 0.175 0.87 -- --
Eh Cysteine (mV) -0.03 0.664 -- --
Eh Glutathione (mV) 0.219 0.001 0.06 NS
BMI: Body Mass Index, CRP: C - reactive protein, LA: Left atrium LVEF: Left Ventricular Ejection Fraction, MI: Myocardial Infarction
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